{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000035","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.232275+00:00","generated_at":"2026-06-05T01:23:53.361999+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26","bullets":["Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.","Net loss of $219.7M ($1.66/share) vs net income of $35.4M ($0.24/share) in FY2022.","R&D expenses $71.8M, G&A $40.6M; G&A rose $16.7M on merger costs.","Topline Phase 2b data for Descartes-08 in MG expected mid-2024; Phase 2 SLE study to start 1H24.","Special stockholder meeting March 27, 2024 to vote on preferred conversion and 1:20-1:30 reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000035","json":"https://secwatch.observer/filing/0001453687-24-000035.json","markdown":"https://secwatch.observer/filing/0001453687-24-000035.md","text":"https://secwatch.observer/filing/0001453687-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/0001453687-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/rnac-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:23:53.361999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"971049b97ba2fad9a90dc085898f680b884a7f0c","claim":"Cartesian Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.","evidence_excerpt":"Cartesian Therapeutics, Inc. announced its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/0001453687-24-000035-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}